4.2 Article

Future directions in soft tissue sarcoma treatment

期刊

CURRENT PROBLEMS IN CANCER
卷 43, 期 4, 页码 300-307

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.currproblcancer.2019.06.004

关键词

Sarcoma; Soft tissue sarcoma; Targeted therapy; Immunotherapy; PDGFR alpha; KIT; beta-catenin/APC/NOTCH; IDH mutation; MDM2; EZH2/INI1; ALK fusion; ASPSCR1-TFE3 fusion

类别

向作者/读者索取更多资源

Sarcoma is a broad term for mesenchymal malignancies that arise from soft tissue or bone. Despite classification by histologic subtype, clinical behavior and response to therapy have great variability. Modern genetic sequencing techniques have been able to identify additional genetic variability and subsequently new targeted therapies. In this review, we discuss the current state of STS diagnostics and treatment and explore some of the more promising areas in which progress is being made. We discuss therapies targeting PDGFR alpha/KIT, beta-Catenin/APC/NOTCH, IDH-1/2 mutations, MDM2 amplifications, EZH2/INI1 expression loss, ALK fusion, and ASPSCR1-TFE3 fusion. We also discuss the progress that has been made within immunotherapies. While soft tissue sarcomas still portend a poor prognosis, these targeted therapies and immunotherapies provide treatment with less toxic side effects. (C) 2019 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据